Home Newsfeeds Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Needham analyst Rajvindra Gill reiterates Microchip Technology (NASDAQ:MCHP) with a Buy and maintains $110 price target.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Needham analyst Rajvindra Gill reiterates Microchip Technology (NASDAQ:MCHP) with a Buy and maintains $110 price target.

Market Volatility Drops Sharply After Apple Results, Non-Farm Payroll Data

By Lisa Levin

May 8, 5:39 AM

The S&P 500 closed higher on Friday after Apple Inc (NASDAQ: AAPL) posted upbeat quarterly results. The Dow also notched its biggest single-day percentage gain since Jan. 6.

AAPL

If You Invested $100 In This Stock 20 Years Ago, You Would Have $600 Today

By Benzinga Insights

August 17, 10:22 AM

Vale (NYSE:VALE) has outperformed the market over the past 20 years by 1.77% on an annualized basis producing an average annual return of 9.55%. Currently, Vale has a market capitalization of $62.37 billion.

VALE

A10 Networks Q3 EPS $0.20 Beats $0.18 Estimate, Sales $72.10M Beat $71.02M Estimate

By Benzinga Newsdesk

November 1, 4:30 PM

A10 Networks (NYSE:ATEN) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.18 by 11.11 percent. This is a 17.65 percent increase over earnings of $0.17 per share from the same

ATEN

Regeneron’s Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol

By Vandana Singh

November 30, 11:51 AM

The FDA has accepted Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other…

REGN

Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Related Posts

Market Volatility Drops Sharply After Apple Results, Non-Farm Payroll Data

If You Invested $100 In This Stock 20 Years Ago, You Would Have $600 Today

A10 Networks Q3 EPS $0.20 Beats $0.18 Estimate, Sales $72.10M Beat $71.02M Estimate

Regeneron’s Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol